Cargando…

Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics

Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschini, Marco, Spahn, Martin, Mattei, Agostino, Cheville, John, Karnes, R. Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820857/
https://www.ncbi.nlm.nih.gov/pubmed/27044421
http://dx.doi.org/10.1186/s12916-016-0613-7
_version_ 1782425480309243904
author Moschini, Marco
Spahn, Martin
Mattei, Agostino
Cheville, John
Karnes, R. Jeffrey
author_facet Moschini, Marco
Spahn, Martin
Mattei, Agostino
Cheville, John
Karnes, R. Jeffrey
author_sort Moschini, Marco
collection PubMed
description Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.
format Online
Article
Text
id pubmed-4820857
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48208572016-04-06 Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics Moschini, Marco Spahn, Martin Mattei, Agostino Cheville, John Karnes, R. Jeffrey BMC Med Review Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores. Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present, four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP). Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally, ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics. BioMed Central 2016-04-04 /pmc/articles/PMC4820857/ /pubmed/27044421 http://dx.doi.org/10.1186/s12916-016-0613-7 Text en © Moschini et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Moschini, Marco
Spahn, Martin
Mattei, Agostino
Cheville, John
Karnes, R. Jeffrey
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
title Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
title_full Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
title_fullStr Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
title_full_unstemmed Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
title_short Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
title_sort incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820857/
https://www.ncbi.nlm.nih.gov/pubmed/27044421
http://dx.doi.org/10.1186/s12916-016-0613-7
work_keys_str_mv AT moschinimarco incorporationoftissuebasedgenomicbiomarkersintolocalizedprostatecancerclinics
AT spahnmartin incorporationoftissuebasedgenomicbiomarkersintolocalizedprostatecancerclinics
AT matteiagostino incorporationoftissuebasedgenomicbiomarkersintolocalizedprostatecancerclinics
AT chevillejohn incorporationoftissuebasedgenomicbiomarkersintolocalizedprostatecancerclinics
AT karnesrjeffrey incorporationoftissuebasedgenomicbiomarkersintolocalizedprostatecancerclinics